News >

Venetoclax/Ibrutinib Combo Impresses in MCL

Jason Harris
Published: Thursday, Apr 05, 2018

Dr Constantine S. Tam

Constantine S. Tam, MD
The combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) induced a 16-week complete response (CR) rate of 42% per CT imaging in patients with previously untreated or relapsed/refractory mantle cell lymphoma (MCL).

Fourteen (58%) patients experienced serious AEs. Six patients died during the study, 4 of which were due to disease progression. Of the other 2 deaths, 1 patient died from malignant otitis externa during week 6 after treatment with ibrutinib alone and the other died from cardiac failure during ongoing complete response.
Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma [published online March 29, 2018]. N Engl J Med. 2018; 378:1211-23. doi: 10.1056/NEJMoa1715519.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x